The merger of Karessa Pharma Holding AB with Klaria Pharma Holding AB is  executed. March 2 was the last trading day for the Karessa share on the Nasdaq First North Growth Market, after which the company was delisted.

On March 6, 2020, the Swedish Companies Registration Office registered the merger, and Karessa Pharma Holding AB ceased. Subsequently, registered shareholders in Karessa received shares in Klaria Pharma Holding AB, where one share in Karessa was exchanged for 0.6032 shares in Klaria. Only entire shares were obtained, the remainder were merged in total in Klaria's shares, sold, distributed and deposited into each owners´account.

Karessa merged into Klaria in total, including the two subsidiaries. The website for Karessa will be closed down shortly and we refer to Klaria's website.

We would like to thank all shareholders in Karessa for your commitment and support of the Company, and believe that the merger with Klaria will greatly increase the conditions for successful projects with the patented alginate film. Already today Klaria has products in collaboration projects with international pharmaceutical companies.

For further information please contact Mats Nilsson, former CEO +46 8 768 2233 or Jesper Wiklund, CEO Klaria Holding +46 8 446 4299



Press releases



Merger with Klaria Pharma Holding

The board of directors of Karessa and Klaria agreed November 5, 2019, on a combination of Klaria and Karessa through a statutory merger. The merger requires support from extra general meetings in both companies.

New directors of the board

Neal Meacham and Kristina Lidén Mascher were elected to the board of Karessa Pharma Holding AB October 22, 2019. 

New Chairman of the Board

Fredrik Hübinette was elected August 22, 2019, as new Chairman of the Board of Karessa. Fredrik, who has a long background in the industry, is behind the invention and the patent on which Karessa's various projects are based.

Karessa meets with investors and partners

Karessa presented the company and its business model and the latest developments at Småbolagsdagen on June 3, organized by Aktiespararna. The meeting was well attended and gave rise to positive discussions. The company was also represented at the Biotech Hanse Forum on June 13 with a presentation.

Karessa also attended the big meeting NLS days in Malmö September 10-12 where we presented Karessa and discussed the company's projects with prospective international business partners.

Annual general meeting 2019, Karessa

The annual general meeting was held April 25, 2019. Ulf Lindberg, Stefan Arver and Scott Boyer was reelected as board members. Please refer to "Investerare" in Swedish part of web page for more information of decisions taken.

Karessa at BIO-Europe Spring

Karessa participated at the congress in Wienna in March 2019 where biotech companies gathered for individual meetings on opportunities for future collaborations. We presented Karessa and its unique drug delivery technology and research. 1 500 companies and 15 000 delegates participated.

Exciting development of the patented drug delivery platform

Karessa is developing pharmaceuticals based on the unique patented alginate drug delivery technique, where the pharmaceutical is placed in the buccal cavity for direct absorption into the bloodstream. This is also used by the Swedish research company Klaria, which on January 22, 2019, signed an agreement with Purdue Pharma regarding development of Adrenalin for the treatment of acute allergic conditions. The agreement is worth close to 500 million SEK and is the second product in the cooperation. We are seeing an increasing interest in our technology with a quick, direct and effective delivery of the pharmaceutical from the buccal cavity into the bloodstream.

Karessa at NLS days

NLS days were held on September 10-12, 2018, in Stockholm. The meeting gathered about 800 companies and organizations in life science, with 1,200 participants. Karessa participated, among other things with a presentation of the company's business concept and projects within erectile dysfunction facing potential stakeholders and partners.

High frequency of sexual problems associated with prostate cancer

In a new published Scandinavian study on treated prostate cancer patients, patients who were sexually active received major problems with sex life afterwards. Erectile dysfunction and accompanying problems were measured at 72–92% among patients from Scandinavia, and were several times more common than untreated patients. The study highlights the importance of clinical need to care for these patients and help them to improve sexual health and quality of life. 

Karessa's work is mentioned

New article about Karessa's unique platform and development work with drugs to treat erectile dysfunction.

Read the article (in Swedish) ”Utvecklar läkemedel mot impotens” 
(December 2017)

undefined40 per cent of all 40-year-old men are affected

40 per cent of all 40-year-old men suffer from erectile dysfunction, i.e. the inability to achieve and maintain an erection sufficient to enable successful intercourse. The reasons may be physical, mental, or a combination of both. The biggest underlying factors include age, other medications and lifestyle.

Read more about the market for medicinal products treating erectile dysfunction here.